Here is a collection of articles I have found both relevant and timely in respects to the life science and healthcare industry over the past week or so.
- There are 503 pages in the new tax law – 12 of those pages could dramatically impact the Private Equity sector (The American Prospect)
- Investment in Digital Health was $3.4B in the first half of 2018, a new record (Biopharmadive). Speaking of investments, over $100B has been spent so far on M&A activity in biopharma in the first half of 2018. Here is a great rundown of all the deals that were announced (Biospace).
- Will the data from the Biogen/Eisai Alzheimer’s trial pan out or is it really just a smoke screen (Forbes).
- Medtech investing advice from the trenches (Medical Design & Outsourcing).
- Millennial parents divided in their trust of healthcare AI. Confidence varied greatly between countries, particularly between Asian, where confidence is high, and Western countries (Verdict Medical Devices)
- And so it continues…Biopharma IPOs gone wild: Highest amount ever raised as 14 companies join public ranks (Clarivate)
- Earlier this week the Centers for Medicare and Medicaid Services withdrew its outcomes-based payment deal for Novartis’ CAR-T therapy, Kymriah, without public acknowledgement. Was this a missed opportunity (Rachel Sachs)?
- Q&A with David M. Sabow, Group Head of Life Sciences for Silicon Valley Bank, Client Funds and Bank Products, on the investments being made in the biopharma space (SVB).
Let me know what you are reading by leaving a link in the comments section.